EFFECT OF REMDESIVIR TREATMENT ON CLINICAL OUTCOME IN HOSPITALIZED PATIENTS WITH COVID-19 IN KIRKUK CITY

Assad Mubarak Jabbar; Abdulla Kamil Abdulla

doi:10.46903/gjms/24.1.2034

EFFECT OF REMDESIVIR TREATMENT ON CLINICAL OUTCOME IN HOSPITALIZED PATIENTS WITH COVID-19 IN KIRKUK CITY

Assad Mubarak Jabbar, Abdulla Kamil Abdulla

Abstract

Background: One of the greatest pandemic illnesses of the century, Coronavirus Disease 2019 (COVID-19), is an infectious disease brought on by the SARS-CoV-2 virus, which causes severe acute respiratory syndrome. Currently, Remdesivir (RDV) is thought to be the only antiviral medication that has received complete approval for treating COVID-19 in hospitalized patients who are 12 years of age or older. The objective of the study was to evaluate RDV’s effectiveness in reducing death and length of stay in patients admitted with Covid-19.

Materials & methods: This prospective cohort study was conducted among 341 hospitalized COVID-19 patients admitted to the isolation units at Azadi Teaching Hospital and Rizgari Hospital in Kirkuk City between February and August 2021. Participants were divided into two groups: the remdesivir group comprising 120 patients who received remdesivir plus standard treatment, and the control group consisting of 221 patients who received standard management without remdesivir. All patients were followed until discharge, ICU admission, or death, and clinical outcomes were compared between the two groups.

Results: After initiation of RDV there were significant reduction in deaths among RDV group in comparison to control group (p=0.0001). there was significant lower mean time to discharge from hospital among RDV group (15 days) in comparison to control group (17 days) (p=0.0001).

Conclusions: Receiving RDV plus standard regimen is effective in reducing mortality and duration of hospitalization among patient with COVID-19 in comparison to standard regimen without RDV.

Keywords

Anti-viral; Covid; Medicines; Mortality; Remdesivir.

Full Text:

PDF

References

Maghsoodi E, Vanaki Z, Mohammadi E. Nurses’ perception of work and life under COVID-19 pandemic conditions: a qualitative study. Front Public Health. 2023;11:1292664. https://doi.org/10.3389/fpubh.2023.1292664

Kamal BJ, Khalaf MA. Impact of COVID-19 on asthma control in Kirkuk City: an analysis of post-pandemic trends. J Med Life. 2024;17(3):292.

Abdulla AK, AL-Barzinji RMG, Taher CA. Open reading frame 8 gene sequence variation of coronavirus in patients from Erbil City, Iraq. Gomal J Med Sci. 2024;22(1):44–51.

Kilmarx PH, Glass RI. Building global health research capacity to address research imperatives following the COVID-19 pandemic. PLoS Med. 2021;18(8):e1003753. https://doi.org/10.1371/journal.pmed.1003753

Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from SARS-CoV-2 with high potency. J Biol Chem. 2020;295(20):6785–97. https://doi.org/10.1074/jbc.RA120.013679

Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–57. https://doi.org/10.1001/jama.2020.16349

FDA. FDA approves first treatment for COVID-19. 2020. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19

Ison MG, Wolfe C, Boucher HW. Emergency use authorization of Remdesivir: the need for a transparent distribution process. JAMA. 2020;323(23):2365–6. https://doi.org/10.1001/jama.2020.8863

WHO. WHO recommends against the use of Remdesivir in COVID-19 patients. Available from: https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients

Azimi P, Keshavarz Z, Cedeno Laurent JG, Stephens B, Allen JG. Mechanistic transmission modeling of COVID-19 on the Diamond Princess cruise ship demonstrates the importance of aerosol transmission. Proc Natl Acad Sci U S A. 2021;118(8):e2015482118. https://doi.org/10.1073/pnas.2015482118

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 – final report. N Engl J Med. 2020;383(19):1813–26. https://doi.org/10.1056/nejmoa2007764

Greene DN, Jackson ML, Hillyard DR, Delgado JC, Schmidt RL. Decreasing median age of COVID-19 cases in the United States – changing epidemiology or changing surveillance? PLoS One. 2020;15(10):e0240783. https://doi.org/10.1371/journal.pone.0240783

Harrington DP, Baden LR, Hogan JW. A large, simple trial leading to complex questions. N Engl J Med. 2021;384(6):576–7. https://doi.org/10.1056/nejme2034294

Bansal V, Mahapure KS, Bhurwal A, Gupta I, Hassanain S, Makadia J, et al. Mortality benefit of Remdesivir in COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2020;7:606429. https://doi.org/10.3389/fmed.2020.606429

Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152. https://doi.org/10.3389/fpubh.2020.00152

Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed COVID-19 – COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–64. https://doi.org/10.15585/mmwr.mm6915e3

Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389–99. https://doi.org/10.1080/10408363.2020.1770685

Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al. Prognostic value of C-reactive protein in patients with COVID-19. Clin Infect Dis. 2020;71(16):2174–9. https://doi.org/10.1093/cid/ciaa641

Lee S, Santarelli A, Caine K, Schritter S, Dietrich T, Ashurst J. Remdesivir for the treatment of severe COVID-19: a community hospital’s experience. J Am Osteopath Assoc. 2020;120(12):926–33. https://doi.org/10.7556/jaoa.2020.156

Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80(5):e1–e6. https://doi.org/10.1016/j.jinf.2020.03.004

Yokoyama Y, Briasoulis A, Takagi H, Kuno T. Effect of Remdesivir on patients with COVID-19: a network meta-analysis of randomized control trials. Virus Res. 2020;288:198137. https://doi.org/10.1016/j.virusres.2020.198137

Chokkalingam AP, Hayden J, Goldman JD, Li H, Asubonteng J, Mozaffari E, et al. Association of Remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States. JAMA Netw Open. 2022;5(12):e2244505. https://doi.org/10.1001/jamanetworkopen.2022.44505

Gupte V, Hegde R, Sawant S, Kalathingal K, Jadhav S, Malabade R, et al. Safety and clinical outcomes of Remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. BMC Infect Dis. 2022;22(1):1. https://doi.org/10.1186/s12879-021-07004-8

DOI: https://doi.org/10.46903/gjms/24.1.2034